AWARD NUMBER: W81XWH-13-1-0404

TITLE: Targeting Nuclear FGF Receptor to Improve Chemotherapy Response in Triple-Negative Breast Cancer

PRINCIPAL INVESTIGATOR: Robin E. Bachelder, Ph.D.

CONTRACTING ORGANIZATION: Duke University
Durham, NC 27705

REPORT DATE: October 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
### 1. REPORT DATE
October 2015

### 2. REPORT TYPE
Annual

### 3. DATES COVERED
30 Sep 2014 - 29 Sep 2015

### 4. TITLE AND SUBTITLE
Targeting Nuclear FGF Receptor to Improve Chemotherapy response in Triple-Negative Breast Cancer

### 6. AUTHOR(S)
Dr. Robin E. Bachelder

E-Mail: robin.bachelder@duke.edu

### 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Duke University
2200 W Main St STE710
Durham, N.C. 27705-4677

### 8. PERFORMING ORGANIZATION REPORT NUMBER
31

### 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

### 10. SPONSOR/MONITOR’S ACRONYM(S)
USAMRMC

### 11. SPONSOR/MONITOR’S REPORT NUMBER(S)

### 12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

### 13. SUPPLEMENTARY NOTES

### 14. ABSTRACT:
Our studies during this grant period identified a function for nuclear basic fibroblast growth factor (bFGF) in TN breast cancer chemo-resistance using a short-term chemotherapy treatment model of resistance. We also showed that nuclear bFGF expression was increased in tumor cells of TN breast cancer patients post-chemotherapy treatment, validating our *in vitro* model. We determined that FGF receptor 1 (FGFR1) protein, but not FGF receptor 3 (FGFR3) protein, was upregulated in chemoresistant SUM159 tumor cells (compared to that in untreated SUM159 cells). SUM159 TN tumor cell lines expressing FGFR1 shRNAs or control shRNAs were produced. Using these lines, we showed that FGFR1 knockdown reduces Snail-1 protein levels, providing support for our hypothesis that an FGF receptor regulates Snail-1 transcription to drive chemotherapy resistance. We will use these shRNA transfectants in year 3 to investigate a function for an FGFR1/Snail-1 signaling axis in TN breast cancer chemo-resistance. Having shown in year 1 that FGFR inhibitors block the growth of chemoresistant TN breast tumor cells, we will investigate the hypothesis in year 3 that this activity is attributable to FGFR inhibitor suppression of FGFR1 activity. Finally, we will optimize an IHC protocol for detecting FGFR1 in tumor cells of TNBC patients pre- and post- neoadjuvant chemotherapy treatment. These studies will investigate FGFR1 as a marker of chemo-resistance in TN breast cancer patients.

### 15. SUBJECT TERMS
- triple-negative breast cancer
- chemo-resistance
- FGF receptor

### 16. SECURITY CLASSIFICATION OF:
- a. REPORT
  Unclassified
- b. ABSTRACT
  Unclassified
- c. THIS PAGE
  Unclassified
- 17. LIMITATION OF ABSTRACT
  UU
- 18. NUMBER OF PAGES
  31
- 19a. NAME OF RESPONSIBLE PERSON
  USAMRMC
- 19b. TELEPHONE NUMBER (include area code)

Standard Form 298 (Rev. 8-98)  
Prescribed by ANSI Std. Z39.18
# Table of Contents

1. Introduction ................................................................. 4-5
2. Keywords ................................................................. 5
3. Overall Project Summary ............................................... 5-8
4. Key Research Accomplishments ..................................... 9
5. Conclusion ............................................................... 10
7. Inventions, Patents and Licenses .................................... 10
8. Reportable Outcomes ..................................................... 10
9. Other Achievements ...................................................... 10
10. References ............................................................... 11
11. Appendices ............................................................. 12-31
PROGRESS REPORT:

INTRODUCTION:

In the previous grant cycle, we optimized a short-term chemotherapy treatment model for identifying determinants of triple-negative (TN) breast tumor cell chemo-resistance (1). To address our hypothesis that Fibroblast growth factor (FGF) receptors drive resistance in TN breast cancer, we utilized a receptor tyrosine kinase signaling antibody array kit to identify highly phosphorylated FGF receptors in chemo-resistant TN tumor cells emanating from our short-term chemotherapy treatment model. In our last progress report, using this receptor signaling array, we showed that FGFR3 was the most highly tyrosine phosphorylated tyrosine kinase receptor in TN breast tumor cells. Based on this finding, in the current grant period, we addressed the hypothesis that FGFR3 drives chemotherapy resistance in TN breast cancer. First, we followed up on the phospho-receptor array data by performing western blotting to determine total FGFR3 levels in TN breast tumor cells. In fact, we were unable to detect FGFR3 protein in any triple-negative breast tumor cell line by immunoblotting, testing various FGFR3 antibodies. Thus, we concluded that the phospho-FGFR3 signal in the receptor tyrosine kinase array was an artifact.

Our receptor tyrosine kinase array also identified FGFR1 to be phosphorylated in TN breast tumor cells, Accordingly, in the current grant period, we investigated FGFR1 protein expression in parental and chemo-resistant TN tumor cells emanating from our short-term chemotherapy treatment model by performing western blotting. We observed significant upregulation of FGFR1 protein levels in chemo-resistant relative to parental SUM159 cells. Based on these findings, we produced SUM159 tumor cells stably expressing a control shRNA or either of five distinct FGFR1 shRNAs to establish a model for studying FGFR1 regulation of TN breast cancer chemo-resistance. We first investigated the impact of FGFR1 knockdown on signaling in untreated SUM159 cells. Fibroblast growth factor receptor 2 (FRS2) is a docking protein that transmits signals from FGF receptors. FRS2 is activated by tyrosine phosphorylation. Notably, we detected significantly reduced phospho-FRS2 in FGFR1 shRNA-expressing compared to control shRNA-expressing TN tumor cells, suggesting that SUM159 TN tumor cells support FGFR1 signaling. Based on our hypothesis that an FGF receptor drives TN tumor cell chemo-resistance by stimulating Snail-1, we next studied effects of FGFR1 knockdown on Snail-1 expression level. Supporting our hypothesis, we observed reduced Snail-1 protein levels in FGFR1 shRNA-expressing compared to control shRNA-expressing TN tumor cells. Chemo-resistance of these FGFR1 shRNA clones will be studied in the next grant cycle. Likewise, Snail-1 shRNA-expressing SUM159 cells will be produced, and chemo-resistance will be studied.

In parallel studies, we also investigated whether the FGFR ligand basic FGF (bFGF) drives chemo-resistance in TNBC. First we constructed triple-negative breast cancer cell lines stably expressing bFGF shRNAs. Using two different bFGF shRNA targeting sequences, we observed that bFGF is essential for chemotherapy resistance of two distinct TN breast tumor cell lines. bFGF is synthesized as two alternative translation products: a cytosolic secreted form [Low molecular weight (LMW), 18 kDa] is synthesized using CAP-dependent translation, whereas a nuclear form [High molecular weight (HMW), 24 kDa] is synthesized using the CAP-independent translation pathway. We next investigated which bFGF translation product is upregulated in chemo-residual TN breast tumor cells emanating from our model. We observed increased HMW (nuclear) bFGF, but not LMW (cytosolic) bFGF, in chemo-residual TNBC cells from our model. To determine the importance of this nuclear localized bFGF variant for TNBC chemo-resistance, we made bFGF shRNA transfectants that co-expressed either high molecular weight (HMW) or low molecular weight (LMW) bFGF. Our results demonstrated that the HMW bFGF construct, but not the LMW construct, was able to restore chemotherapy resistance of bFGF shRNA cells. We went on to demonstrate that HMW bFGF drives DNA repair in TN breast tumor cells, attributing to its role in chemo-resistance. To begin to investigate the translational relevance of our findings, we showed by immunohistochemistry that HMW bFGF expression is increased in tumor tissues from TN breast cancer patients post neoadjuvant chemotherapy treatment (compared to pre-treatment). Based on these collective findings, we published a manuscript in Breast Cancer Research describing a novel function for HMW bFGF in TNBC chemo-resistance (2).

Collectively our data from the past two years of this grant period indicate that nuclear bFGF (HMW bFGF), drives TN breast cancer chemo-resistance. An important follow up study is to determine how this pathway can
be targeted to eliminate chemo-resistant TN breast tumor cells. We hypothesize that an FGF receptor supports nuclear bFGF signaling. Based on our observation that FGFR1 is upregulated in chemo-resistant SUM159 tumor cells generated from our short-term chemotherapy treatment model, in the next grant cycle, we will devote our efforts to showing that FGFR1 drives TN breast cancer chemo-resistance. We will test the hypothesis that FGFR inhibitors can eliminate chemo-resistant TN tumor cells by suppressing FGFR1 signaling.

**KEYWORDS:** chemotherapy resistance, triple-negative breast cancer, FGF receptor

**OVERALL PROJECT SUMMARY (Tasks refer to those outlined in approved Statement of Work):**

**Goal 1: Examine FGFR3 regulation of chemotherapy resistance in triple-negative breast tumor cells.**

**Task 1 (Months 13-15):** Examine the ability of DNA-damaging (Adriamycin, Cyclophosphamide) and microtubule-targeting (Docetaxel) chemotherapies to select for triple-negative tumor cells expressing FGFR3.

**RESULTS/DISCUSSION:** During the first year of this grant, we developed an *in vitro* model of TN breast cancer dormancy/recurrence (Li et al., 2014). These studies indicate that TN breast tumor cells exposed for 2 days to chemotherapy continue to die for 7 days after initial chemotherapy treatment (Fig. 1A). Approximately two weeks after chemotherapy removal, chemotherapy resistant colonies were harvested in order to identify unique signaling pathways that drive chemotherapy resistance. In the current grant cycle (year 2), we demonstrated that nuclear bFGF is a determinant of chemotherapy resistance using this model (2). To validate relevance of our findings to TNBC patients, we showed that nuclear bFGF expression in tumor cells of TNBC patients increases post-chemotherapy treatment (2). The aims of this grant are to address whether a bFGF receptor is a targetable determinant of TN breast cancer chemo-resistance.

In the past year, we used our validated chemo-resistance model to investigate the hypothesis that FGFR3 is a determinant of TNBC chemo-resistance. This hypothesis was founded on our results from grant period 1, showing that TN breast tumor cells are associated with high levels of phospho-FGFR3 (as determined using a receptor tyrosine kinase signaling antibody array kit). In the current grant term, we followed up on this array data, investigating total FGFR3 protein levels in TN breast tumor cells. In fact, we were unable to detect FGFR3 protein in any triple-negative breast tumor cell line by immunoblotting (data not shown), suggesting that the phospho-FGFR3 signal in the array was an artifact.

Based on our knowledge that FGFR inhibitors prevent chemo-resistant TN breast tumor cell colony growth in our model (data obtained in year 1), we sought to determine which bFGF receptor family member is important for resistance. By western blotting, we observed that FGFR1 protein is upregulated four-fold in chemo-resistant compared to parental SUM159 cells from our model (Fig. 1B). One of the aims of this grant is to test the hypothesis that an FGF receptor drives Snail-1 transcription. To begin to address this hypothesis, we measured Snail-1 levels in chemo-resistant tumor cell cells from our model. As shown in Fig. 2B, chemo-resistant tumor cells expressed 4-fold higher levels of Snail-1 than untreated tumor cells.

RESULTS/DISCUSSION: We did not complete these studies in year 2 of this grant because we were unable to detect FGFR3 in in either SUM159 tumor cells or chemo-resistant SUM159 tumor cells emanating from our short-term chemotherapy treatment model. Because we showed in year 2 that FGFR1 is upregulated in chemo-resistant SUM159 cells (Fig. 1B), we will investigate FGFR1 phosphorylation/kinase activity in our chemo-resistance model during year 3.


RESULTS/DISCUSSION: Studies of FGFR3 were not pursued in year 2 because we did not detect FGFR3 protein in chemo-resistant TNBC cells by western blotting. However, in year 2, we did observe increased FGFR1 protein in chemo-resistant compared to untreated SUM159 tumor cells. Accordingly, we initiated
studies to test the hypothesis that FGFR1/Snail-1 regulates chemotherapy resistance in triple-negative breast tumor cells. SUM159 tumor cells were stably transfected with either of five FGFR1 shRNAs or a control shRNA. As shown in Fig. 2A, three of the five FGFR1 shRNA-expressing cell lines showed efficient knockdown of FGFR1 (3-fold FGFR1 reduction in sh02 cells and 8-fold FGFR1 reduction in sh05 cells). To begin to determine if FGFR1 knockdown reduces FGFR1 activity in these cells, we probed total cell lysates from control shRNA-expressing and FGFR1 shRNA-expressing cells with antibodies specific for phospho-FRS2 and FRS2. FRS2 is an FGFR-associated docking protein that: 1) is essential for FGFR signaling, and 2) becomes phosphorylated on tyrosine residue 196 upon activation of FGFR family members. As shown in Fig. 2B, knocking down FGFR1 expression levels in SUM159 cells reduced phospho-FRS2(Tyr196) levels. To begin to test the hypothesis that FGFR1 drives Snail-1 expression, we also probed total cellular proteins from control shRNA-expressing and FGFR1 shRNA-expressing cells with a Snail-1 antibody. As shown in Fig. 2B, FGFR1 shRNA-transfected cells expressed two-fold reduced levels of Snail-1 protein (compared to control shRNA transfectants). These FGFR1 knockdown cells will allow us to determine in year 3 whether FGFR1 regulates SUM159 tumor cell chemo-resistance. We will also test this hypothesis in MDA-MB-231 TN tumor cells by producing FGFR1 shRNA transfectants of this cell line.

**Figure 2:** SUM159 cells were stably transfected with a control shRNA or either of five FGFR1 shRNAs (Sigma). FGFR1 knockdown was assessed by immunoblotting equivalent amounts of protein with an FGFR1 (Cell Signaling Technology) or actin (Sigma) antibody. Equivalent amounts of total cellular protein were extracted from SUM159 cells expressing control shRNA or FGFR1 shRNA #05, subjected to SDS-PAGE, and immunoblotted with antibodies specific for FGFR1, phospho-FRS2 (Tyr196), FRS2, or Snail-1 (all antibodies from Cell Signaling Technology), followed by IRdye-conjugated secondary antibody. Bands were detected by Odyssey Infrared Imaging. Protein bands were quantified by densitometry using Image J software (NIH).

**Task 4 (Months 22-24):** Test the hypothesis that FGFR3 drives AP-1-dependent Snail-1 transcription in chemotherapy-selected triple-negative breast tumor cells.

**RESULTS/DISCUSSION:** These studies are delayed due to complications in identifying FGFR family members important for TN breast cancer chemo-resistance. Studies in year 3 will address the ability of FGFR1 to drive AP-1-dependent Snail-1 transcription.
Task 5 (Months 19-24): By immunohistochemistry (IHC), examine FGFR3 expression in tumor cells obtained from triple-negative breast cancer patients pre- and post- neoadjuvant chemotherapy treatment [Adriamycin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)].

Task 5a (already completed): Obtain human subjects approval.

Task 5b (Months 19-21): Optimize an IHC protocol for detecting FGFR3 in triple-negative breast cancers.

RESULTS/DISCUSSION: We are delayed in this task because we did not detect FGFR3 protein in TNBC cells in vitro. In year 3, we will optimize an IHC protocol for detecting FGFR1 in TN breast cancers [considering that our results from year 2 show that FGFR1 protein levels are increased in TN tumor cells surviving short-term chemotherapy in vitro (Fig. 1)].

Task 5c (already completed): Identify/obtain relevant retrospective triple-negative breast cancer patient samples.


RESULTS/DISCUSSION: We are delayed for the same reasons discussed for Task 5b. After optimizing an FGFR1 IHC protocol in year 3, we will apply this protocol to our identified, matched TNBC cases obtained pre- and post- neoadjuvant chemotherapy treatment.
KEY RESEARCH ACCOMPLISHMENTS:

- Published a manuscript showing that bFGF is a critical determinant of chemotherapy resistance in TN breast cancer (2).
- Validated that bFGF is expressed in residual tumor cells from TN breast cancer patients post-neoadjuvant chemotherapy treatment, showing relevance of our *in vitro* model to patients (2).
- Showed that FGFR1 protein levels are increased in chemo-resistant SUM159 tumor cells emanating from our short-term chemotherapy treatment model (compared to levels in untreated SUM159 cells).
- Demonstrated that Snail-1 expression is reduced in FGFR1 shRNA-expressing SUM159 cells (compared to control shRNA-expressing SUM159 cells), suggesting that FGFR1 regulates expression of Snail-1, a transcriptional repressor linked to chemo-resistance.
CONCLUSION: Our studies during this grant period identified a function for nuclear bFGF in TN breast cancer chemo-resistance. Nuclear bFGF expression was also increased in tumor cells of TN breast cancer patients post-chemotherapy treatment, validating our in vitro model. Our in vitro studies showed that FGFR1 protein, but not FGFR3 protein, is upregulated in chemotherapy-resistant SUM159 tumor cells (compared to that in untreated SUM159 cells). Based on this result, we established SUM159 cell lines expressing FGFR1 shRNAs or control shRNAs. Using these transfectants, we showed that FGFR1 knockdown reduces Snail-1 protein levels, providing support for our hypothesis that an FGF receptor regulates Snail-1 transcription to drive chemotherapy resistance. We will use these shRNA transfectants in year 3 to investigate a function for an FGFR1/Snail-1 signaling axis in TN breast cancer chemo-resistance. Having shown that FGFR inhibitors block the growth of chemo-resistant TN breast tumor cells (year 1), we will also investigate the hypothesis in year 3 that this activity is attributable to FGFR inhibitor suppression of FGFR1. Finally, in year 3 we will optimize an IHC protocol for detecting FGFR1 in tumor cells of TNBC patients pre- and post- neoadjuvant chemotherapy treatment. These studies will investigate FGFR1 as a marker of chemo-resistance in TN breast cancer patients.

PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

Peer-reviewed scientific journals:


Abstracts: N/A

Presentations:

2015 Duke University School of Medicine, Tumor Biology Seminars. “Nuclear bFGF drives triple-negative breast cancer chemotherapy resistance”.

2015 Duke University Medical Center, Department of Pathology Grand Rounds. “Targeting chemotherapy-enriched dormant tumor cells to prevent triple-negative tumor recurrence”.

INVENTIONS, PATENTS, AND LICENSES: Nothing to report

REPORTABLE OUTCOMES:

1. Publication showing that nuclear bFGF is a critical determinant of TN breast cancer chemo-resistance.
2. Generation of FGFR1 shRNA-expressing and control shRNA-expressing TN tumor cells for assessing FGFR1 regulation of chemo-resistance in year 3 of this grant.

OTHER ACHIEVEMENTS: Nothing to report.
REFERENCES:


APPENDICES:

REVISED STATEMENT OF WORK:

Goal 1: Examine FGFR1 regulation of chemotherapy resistance in triple-negative breast tumor cells.

Task 1 (Months 25-26): Examine the ability of DNA-damaging (Adriamycin, Cyclophosphamide) and microtubule-targeting (Docetaxel) chemotherapies to select for triple-negative tumor cells expressing FGFR1.

Incubate two triple-negative tumor cell lines (MDA-MB-231, SUM159PT) in vitro for 2 d +/- chemotherapy [Adriamycin (50, 25, 10, 5, 1 ng/mL), Docetaxel (100 nM, 50 nM, 25 nM, 10 nM, 1 nM), or the active form of Cyclophosphamide (4-hydroperoxy-cyclophosphamide, 4-HC; 0.1, 1, 5, 10, 25 µM)] or vehicle alone. Obtain nuclear and non-nuclear (cytoplasmic + cell membrane) extracts from chemo-residual tumor cells obtained on d8 and from chemo-resistant colonies harvested on d18. Immunoblot equivalent amounts of nuclear and non-nuclear proteins with antibodies specific for FGFR1, Lamin A (nuclear loading control), or tubulin-specific (non-nuclear loading control). For the purpose of generating preliminary data for this grant proposal, MDA-MB-231 and SUM159PT cells were already obtained from the Duke Cell Culture facility. SUM159PT cells were provided by this facility after obtaining permission for distribution from Dr. Gayathri Devi.

Outcome: These studies will determine the ability of different chemotherapy regimens to enrich for FGFR1-expressing TN tumor cells.

Task 2 (Month 27): Investigate FGFR1 phosphorylation/kinase activity in triple-negative breast tumor cells exposed to DNA-damaging and microtubule-targeting chemotherapies.

Incubate triple-negative tumor cells +/- chemotherapy as in Task 1. To measure tyrosine phosphorylated FGFR1, immunoprecipitate FGFR1 from extracts of these cells, and immunoblot with pan phospho-tyrosine antibody. Measure FGFR1 kinase activity by performing in vitro kinase assays on FGFR1 immunoprecipitates.

Outcome: These studies will determine the activity of FGFR1 in chemotherapy-resistant triple-negative tumor cells.

Task 3 (Months 27-30): Using shRNAs, investigate FGFR1/Snail-1 regulation of chemotherapy resistance (Adriamycin vs Cyclophosphamide vs Docetaxel) in triple-negative breast tumor cells.

Task 3a (Months 27-28): Investigate FGFR1 regulation of chemotherapy resistance in triple-negative breast tumor cells.

Incubate FGFR1 shRNA-expressing and control shRNA-expressing TN tumor cells +/- chemotherapy (Adriamycin or Cyclophosphamide or Docetaxel) for 2d. Determine cell viability on d8 using Alamar Blue (Invitrogen) and trypan blue assays. Count chemo-resistant colonies on d18.


Transfect TN tumor cells with Snail-1 shRNAs or a control shRNA. Incubate transfectants +/-chemotherapy as in Task 1. Test cell viability as in task 3A. Count chemo-resistant colonies as in Task 3a.

Outcome: We will determine whether FGFR1 and Snail-1 drive chemotherapy resistance in TN breast tumor cells.
**Task 4 (Months 31-36):** Test the hypothesis that FGFR1 drives AP-1-dependent Snail-1 transcription in chemotherapy-selected triple-negative breast tumor cells.

Task 4a (Months 31-32): Investigate FGFR1 regulation of c-jun expression.

Incubate FGFR1 shRNA transfectants (from task 3) +/- chemotherapy for 2d. Harvest chemoresidual tumor cells on d8 and cells from chemo-resistant colonies on d18. Extract RNA, and determine c-jun mRNA levels by real time-PCR. Immunoblot equivalent amounts of total cellular protein with c-jun, phospho-c-jun(Ser63), FGFR1, and actin antibodies.

Task 4b (Months 33-34): Investigate FGFR1 regulation of c-jun transcription.

Incubate FGFR1 shRNA transfectants (from task 3) +/- chemotherapy as in Task 4a. Determine c-jun promoter activity using a c-jun promoter-driven luciferase construct. Test association of FGFR1 with the c-jun promoter by chromatin immunoprecipitation (CHIP).

Task 4c (Months 35-36): Assess FGFR1 regulation of activity of AP-1.

After incubating FGFR1 shRNA transfectants (from task 3) +/- chemotherapy as in Task 4a, measure AP-1 activity using an AP-1 reporter luciferase kit (Qiagen).

Task 4d (Months 35-36): Investigate FGFR1 regulation of Snail-1 expression.

Incubate FGFR1 shRNA transfectants (from task 3) +/- chemotherapy as in Task 4a. Measure Snail-1 mRNA, Snail-1 protein, and Snail-1 promoter activity in these transfectants using our published methods(3, 4).

Task 4e (Months 35-36): Determine importance of AP-1 for chemotherapy regulation of Snail-1.

Transfect triple-negative tumor cells with c-jun shRNAs or control shRNAs. Incubate transfectants +/- chemotherapy as in Task 4a. Confirm c-jun knockdown by immunoblotting extracted proteins with c-jun antibody. Determine the ability of chemotherapy to regulate Snail-1 expression/promoter activity in c-jun shRNA and control shRNA transfectants. Test c-jun association with the Snail-1 promoter by CHIP.

**Outcome:** These studies will determine if FGFR1 drives Snail-1 transcription by regulating AP-1 transcription factor in chemo-resistant TN tumor cells.

**Task 5 (Months 25-28):** By immunohistochemistry (IHC), examine FGFR1 expression in tumor cells obtained from triple-negative breast cancer patients pre- and post- neoadjuvant chemotherapy treatment [Adriamycin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)].

Task 5a (already completed): Obtain human subjects approval.

Task 5b (Months 25-26): Optimize an IHC protocol for detecting FGFR1 in triple-negative breast cancers.

Optimize a protocol for detecting FGFR1 in triple-negative tumor cells pre- and post- chemotherapy treatment using cell blocks from tumor cell lines previously shown (by immunoblotting) to be positive [Adriamycin-treated (25 ng/mL) SUM159PT cells] or negative (MCF7 cells) for FGFR1.

Task 5c (already completed): Identify/obtain relevant retrospective triple-negative breast cancer patient samples.
Identify and obtain from National Comprehensive Cancer Network (NCCN) relevant triple-negative breast cancer tissues \([n=40, \text{pre and post-neoadjuvant (AC) therapy (cohort 1); n=40, pre- and post- neoadjuvant (TC) therapy (cohort 2)}]\). Obtain TN breast cancer tissues from Dr. Marcom’s neoadjuvant protocol \([n=40, \text{pre and post-neoadjuvant (AC) therapy (cohort 3); n=40, pre- and post- neoadjuvant (TC) therapy (cohort 4)}]\). Considering that approximately 60% of triple-negative breast cancer patients exhibit an incomplete pathologic response to neoadjuvant chemotherapy treatment\(^{(5)}\), we expect to obtain residual tumor cells post chemotherapy treatment from only 24 patients from each cohort of 40 patients.


Using the protocol optimized in Task 5b, stain the triple-negative breast cancer cases described in Task 5c for FGFR1. Score the \(\%\) FGFR1\(+\) tumor cells for each case (pre and post chemotherapy treatment). For each of the four cohorts, determine the change in \(\%\) FGFR1\(+\) tumor cells from pre- to post- chemotherapy. Estimate mean change with its 80% confidence interval. Use the Wilcoxon signed-rank test (1-sided alpha of 0.025) to test whether the central tendency of this endpoint is greater than zero.

Outcome: We will determine if the percent FGFR1\(+\) tumor cells in triple-negative breast cancers is increased following either AC or TC neoadjuvant chemotherapy treatment.

Goal 2: Perform pre-clinical studies of a novel combination therapy (chemotherapy + FGFR inhibitor) for triple-negative breast cancer (Months 25-36).

Task 6 (Months 25-26): Assess the impact of a selective FGFR inhibitor (Novartis; NVP-BGJ398) on FGFR1 phosphorylation/kinase activity and Snail-1 expression in chemotherapy-resistant triple-negative breast tumor cells.

Incubate triple-negative tumor cells (MDA-MB-231 and SUM159PT) +/- chemotherapy (as described for Task 1) +/- selective FGFR inhibitor [NVP-BGJ398, Novartis; concentrations= 0.05, 1, 5, 10, 50 nM] in 96 well plates. Measure FGFR1 expression/phosphorylation/kinase activity, and Snail-1 expression/promoter activity as in Goal 1.

Outcome: These studies will determine whether an FGFR small molecule inhibits FGFR1 activity and Snail-1 expression in chemotherapy-resistant triple-negative tumor cells.


Incubate tumor cells in vitro +/- chemotherapy +/- NVP-BGJ398 as in Task 6. Determine cell viability on d8 post chemotherapy treatment as in Task 3a. Count recurrent colonies on d18 post chemotherapy-treatment, following the protocol of our published dormancy/recurrence model\(^{(1)}\).

Outcome: These studies will determine whether an FGFR small molecule inhibitor reduces the number of chemo-residual tumor cells/chemo-resistant colonies in an in vitro model of tumor dormancy/recurrence.

Task 8 (Months 30-36): Determine efficacy of combination therapy (chemotherapy + FGFR inhibitor) in eliminating triple-negative tumor cells in an orthotopic mouse model.

Task 8a (Months 27-30): Obtain approval to perform animal work.

Task 8b (Months 31-32): Establish triple-negative tumors in nude mice.

Inject female nude mice (4 weeks old) in the mammary fat pad with \(10^6\) SUM159 cells. Evaluate tumor volume with calipers 3x/week. Once tumors reach 200 mm\(^3\), start treatments (See Task 8c). These studies will employ 180 nude mice (30 mice/treatment x 6 treatments).
Task 8c (Months 33): Treatment of nude mice with combination therapy (chemotherapy + selective FGFR inhibitor).

Randomize mice with tumors (200 mm$^3$) into six treatment groups (30 mice per group): 1) vehicle alone, 2) 4 mg/kg Adriamycin [intravenous (IV)], 3) NVP-BGJ398 (15 mg/kg; oral gavage), 4) NVP-BGJ398 (45 mg/kg; oral gavage), 5) Adriamycin (4 mg/kg; IV) + NVP-BGJ398 (15 mg/kg; oral gavage), and 6) Adriamycin (4 mg/kg; IV) + NVP-BGJ398 (45 mg/kg; oral gavage). Repeat Adriamycin treatments weekly for 14 days. Repeat NVP-BGJ398 treatments daily. Measure tumor volume with calipers 3x/wk for the duration of treatment (14 days). At the end of treatment, excise and snap freeze any residual tumors detected.

Task 8d (Month 34): Perform statistical analysis to determine if combination therapy is more effective than chemotherapy alone in reducing triple-negative tumor volume.

We hypothesize that the median tumor volume at the end of 2 weeks will be significantly smaller in:

a) group 2 (Adriamycin) than in group 1 (vehicle)
b) group 5 (Adriamycin + 15 mg/kg FGFR inhibitor) than in group 2 (Adriamycin)
c) group 6 (Adriamycin + 45 mg/kg FGFR inhibitor) than in group 2 (Adriamycin)
d) group 5 (Adriamycin + 15 mg/kg FGFR inhibitor) than in group 3 (15 mg/kg FGFR inhibitor)
e) group 6 (Adriamycin + 45 mg/kg FGFR inhibitor) than in group 4 (45 mg/kg FGFR inhibitor).

Perform the Wilcoxon rank-sum test with a 1-sided alpha of 0.01 (0.05/5) to test for the significance of each of these five hypothesized group differences. At the end of the study, plot median tumor volume against time for each of the six treatment groups. Use the Wilcoxon rank-sum test to test for a group difference at each of the individual time points.

Task 8e (Months 35-36): Analyze residual tumor cells.

Extract nuclear proteins from residual tumor cells. Immunoprecipitate FGFR1 from equivalent amounts of nuclear extracts, and immunoblot these immunoprecipitated proteins with anti-phospho-tyrosine. Measure FGFR1 and Snail-1 expression in nuclear extracts by immunoblotting.

**Outcome:** Results will establish in an orthotopic mouse model whether a novel combination therapy (Adriamycin + FGFR inhibitor) is more effective than chemotherapy alone in eliminating triple-negative breast tumor cells. They will also determine the ability of this FGFR inhibitor, when combined with chemotherapy, to reduce levels of tyrosine phosphorylated FGFR1 and Snail-1 in triple-negative tumor cells.

**Future Directions:** The proposed work studies the ability of a novel combination therapy (chemotherapy + FGFR inhibitor) to eliminate human triple-negative breast tumor cells more effectively than chemotherapy alone. We will test the efficacy of this combination therapy both in vitro and in an orthotopic mouse model. These pre-clinical studies will provide an essential foundation for a future clinical trial of this combination therapy in triple-negative breast cancer patients. Based on his extensive experience with clinical trials, our collaborator (Paul Kelly Marcom, M.D.) can rapidly translate these findings into human clinical trials. These trials will test efficacy of this combination therapy (compared to efficacy of chemotherapy alone) in: 1) promoting a complete pathologic response in triple-negative breast cancer patients, and 2) prolonging patient survival.

For this proposal, our studies of combination therapy in the orthotopic mouse model are limited to Adriamycin + FGFR inhibitor. If our in vitro studies show that other combination therapies (Docetaxel + FGFR inhibitor; cyclophosphamide + FGFR inhibitor) are more effective than the respective chemotherapy alone in eliminating triple-negative tumor cells, we will in future studies test these alternative combination therapies in an orthotopic mouse model, paving the way for clinical trials of FGFR inhibitors in combination with specific chemotherapy regimens as an effective treatment strategy for triple-negative breast cancer.
Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance

Shenduo Li1, Sturgis Payne1, Fang Wang1, Peter Claus3, Zuowei Su1, Jeffrey Groth1, Joseph Geradts1, Gustaaf de Ridder1, Rebeca Alvarez1, Paul Kelly Marcom2, Salvatore V. Pizzo1 and Robin E. Bachelder1*

Abstract

Introduction: Chemotherapy remains the only available treatment for triple-negative (TN) breast cancer, and most patients exhibit an incomplete pathologic response. Half of patients exhibiting an incomplete pathologic response die within five years of treatment due to chemo-resistant, recurrent tumor growth. Defining molecules responsible for TN breast cancer chemo-resistance is crucial for developing effective combination therapies blocking tumor recurrence. Historically, chemo-resistance studies have relied on long-term chemotherapy selection models that drive genetic mutations conferring cell survival. Other models suggest that tumors are heterogeneous, being composed of both chemo-sensitive and chemo-resistant tumor cell populations. We previously described a short-term chemotherapy treatment model that enriches for chemo-residual TN tumor cells. In the current work, we use this enrichment strategy to identify a novel determinant of TN breast cancer chemotherapy resistance (a nuclear isoform of basic fibroblast growth factor (bFGF)).

Methods: Studies are conducted using our in vitro model of chemotherapy resistance. Short-term chemotherapy treatment enriches for a chemo-residual TN subpopulation that over time resumes proliferation. By western blotting and real-time polymerase chain reaction, we show that this chemotherapy-enriched tumor cell subpopulation expresses nuclear bFGF. The importance of bFGF for survival of these chemo-residual cells is interrogated using short hairpin knockdown strategies. DNA repair capability is assessed by comet assay. Immunohistochemistry (IHC) is used to determine nuclear bFGF expression in TN breast cancer cases pre- and post- neoadjuvant chemotherapy.

Results: TN tumor cells surviving short-term chemotherapy treatment express increased nuclear bFGF. bFGF knockdown reduces the number of chemo-residual TN tumor cells. Adding back a nuclear bFGF construct to bFGF knockdown cells restores their chemo-resistance. Nuclear bFGF-mediated chemo-resistance is associated with increased DNA-dependent protein kinase (DNA-PK) expression and accelerated DNA repair. In fifty-six percent of matched TN breast cancer cases, percent nuclear bFGF-positive tumor cells either increases or remains the same post- neoadjuvant chemotherapy treatment (compared to pre-treatment). These data indicate that in a subset of TN breast cancers, chemotherapy enriches for nuclear bFGF-expressing tumor cells.

Conclusion: These studies identify nuclear bFGF as a protein in a subset of TN breast cancers that likely contributes to drug resistance following standard chemotherapy treatment.
Introduction
Targeted therapies are not available for triple-negative (TN) breast cancer, which lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (HER2) over-expression. Although TN breast tumors initially respond to chemotherapy, this response is incomplete in more than half of these patients [1, 2]. Notably, tumor recurrence is observed within 5 years of treatment in half of patients exhibiting an incomplete pathologic response, resulting in patient mortality [3, 4]. Accumulating evidence indicates that a small population of drug-resistant tumor cells surviving initial chemotherapy treatment is likely responsible for tumor relapse [5–7]. In order to identify new treatment strategies for these aggressive breast cancers, there is an urgent need to identify novel signaling pathways that contribute to TN breast cancer chemo-resistance.

We previously characterized an in vitro model of chemo-resistance/tumor recurrence [8]. In this model, tumor cells were subjected to short-term chemotherapy, which killed 99.9 % of tumor cells. However, a subpopulation (0.1 %) of chemo-resistant tumor cells persisted and resumed proliferation approximately 2 weeks after chemotherapy removal. In the current work, we investigated signaling pathways that drive TN tumor cell chemo-resistance using this in vitro model.

The basic fibroblast growth factor family (FGF) (alternatively known as FGF-2) consists of both cytosolic (secreted) and nuclear isoforms. Expression of these bFGF isoforms is regulated at the level of translation. Specifically, cytosolic forms (low molecular weight, 18 kDa) are regulated by cap-dependent translation, whereas nuclear forms (high molecular weight; 22, 22.5, and 24 kDa) are regulated by cap-independent translation [9]. These isoforms differ in molecular weight because they utilize different translation initiation sites.

Cytosolic (secreted) isoforms of bFGF are implicated in tumor resistance to anti-angiogenic therapy [10–15]. However, functions for nuclear bFGF in cancer cells remain poorly understood. In over-expression models, nuclear bFGF has been reported to regulate cell cycle [16–18], cell survival [19], radio-resistance [20], and tumor metastasis [19, 21]. Moreover, nuclear bFGF expression in astrocytic tumors is associated with a poor patient prognosis [22]. To date, nuclear bFGF expression/function in breast cancer has not been investigated.

DNA repair pathways are frequently de-regulated in breast cancer. Whereas BRCA proteins are responsible for homologous repair, DNA-dependent protein kinase (DNA-PK) repair double-stranded DNA breaks by non-homologous end joining. DNA-PK consists of a catalytic subunit (DNA-PKcs) and a regulatory subunit (Ku70 and Ku80 heterodimer), which recruits DNA-PKcs to DNA. The status of the cell cycle determines whether DNA-PK or BRCA repairs DNA, with DNA-PK being responsible in growth-arrested cells [23].

Previous studies using bFGF over-expression models suggest that nuclear bFGF drives DNA-PKcs transcription [20]; however, the ability of endogenous bFGF to regulate DNA-PKcs expression/DNA repair in tumor cells has not been reported. In the current work, we show that nuclear bFGF promotes survival of chemo-residual TN tumor cells. This bFGF function is associated with increased DNA damage repair mediated by increased DNA-PK expression/activity. Our work identifies nuclear bFGF as a central determinant of TN breast cancer chemo-resistance, and suggests a novel therapeutic target (nuclear bFGF) for preventing TN breast cancer recurrence.

Methods
Cell culture
SUM159 TN breast cancer cells were obtained from the Duke Cell Culture Facility and maintained in Ham’s F-12 medium containing 5 % heat-inactivated FBS, 5 μg/ml insulin, and 1 μg/ml hydrocortisone. BT549 TN breast cancer cells were obtained from the Duke Cell Culture Facility and maintained in RPMI 1640 medium containing 10 % heat-inactivated FBS, 1 μg/ml insulin, 10 mM HEPES, 1 mM pyruvate, and 2.5 g/L glucose.

Generation of chemo-residual tumor cells and subsequent colonies
SUM159 tumor cells were seeded in T225 cell culture flasks (2 × 10^6 cells/flask) and, after 2 days, treated with either 1 μg/ml doxorubicin (Sigma, St Louis, MO, USA) or 100 nM docetaxel (Sigma). The drug was removed after 2 days, and cells were fed new media every third day. The majority of cells (99.9 %) were eliminated by day 7, after which only chemo-residual cells (0.1 %) were observed. BT549 tumor cells were seeded in T225 cell culture flasks (3 × 10^6 cells/flask) and, after 2 days, treated with 0.5 μg/ml doxorubicin. Drug was removed after 2 days, and cells were fed new media every third day. The majority of cells (99.9 %) were eliminated by day 7, after which only chemo-residual cells (0.1 %) were observed. SUM159 and BT549 chemo-residual cells were harvested on day 7 with trypsin-EDTA, and re-plated in 6-well plates. Resumed proliferation of chemo-residual tumor cells was monitored over time. Medium was changed every 3 to 4 days. Colonies evolving from chemo-residual cells were stained with crystal violet and colonies containing >50 cells were counted [24].

For the mammosphere culture, cells were seeded into Mammacult media (Stem cell Tech., Vancouver, BC, Canada; #05620) supplemented with 1 % Methylose (Sigma St Louis, MO, USA; #M0430), penicillin/streptomycin (Life Technologies, Carlsbad, CA, USA), heparin (Stemcell Tech., #07980; 4 μg/mL), and hydrocortisone (1 μg/mL). The sphere assay was setup in Costar 6-Well
Ultra Low Attachment (Corning, NY, USA) plates in triplicate. Cells were incubated at 37 °C/5 % CO2. Spheres were counted with a GelCount cell counter (Oxford Optronix, Milton Park, UK) after 3 to 7 days. For secondary sphere assays, primary spheres were dissociated with trypsin, washed, and seeded at 20,000 cells/well as above.

**Western blots**

Cells were harvested using trypsin-EDTA and washed with PBS. Harvested cells were incubated in cytosolic lysis buffer (10 mM HEPES (pH 7.4), 10 mM KCl, 1.5 mM MgCl₂, 0.5 % NP40, and proteinase inhibitors) on ice for 20 minutes and centrifuged. Supernatants were collected as cytosolic protein lysates. The residual pellets were washed with cytosolic lysis buffer, and then incubated in nuclear lysis buffer (50 mM TRIS (pH 7.5), 1 % SDS, and proteinase inhibitors) plus Benzonase (Sigma) on ice for 20 minutes. The supernatants after centrifugation were collected as nuclear protein extracts. Protein concentrations were determined by biciniconinic acid (BCA) assay. Equivalent amounts of protein were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotted with the following primary antibodies, followed by the appropriate species IRDye-conjugated secondary antibody (Life Technologies, Carlsbad, CA, USA): bFGF (BD Biosciences, Franklin Lakes, NJ, USA; catalog # 610073), Lamin-A (Sigma), DNA-PKCS (Cell Signaling, Beverly, MA, USA; catalog # 4602), phospho-Ser 2056-DNA-PK (Sigma, St Louis, MO; clone # NM_02006.x-635s1c1; catalog # TRCN0000003330) or control shRNA plasmid (Sigma, St Louis, MO, USA; pLKO.1) + Optimem (Life Technologies) and 2 Lipofectamine 2000 (Life Technologies) + Optimem. These mixtures were incubated separately at room temperature for 5 minutes, combined, and incubated for 30 minutes at room temperature. Cells were washed twice with HBSS (Life Technologies). Optimem was then added to the RNA/Lipofectamine mixture, and the mix was added to the cells, which were incubated overnight at 37 °C. This medium was removed the next day and replaced with media containing puromycin (5 μg/ml, SUM159; 2 μg/ml, BT549). Cells were expanded in puromycin and tested for bFGF knockdown by western blotting. For bFGF addback, plasmids [25] expressing 18-kDa rat bFGF, 23-kDa rat bFGF, or an empty control vector were transfected into SUM159 or BT549 cells stably expressing a bFGF shRNA. The transfection protocol was performed as above, except that the cells were selected in puromycin (as above) and G418 (Life Technologies) at 400 μg/ml. Expression of addback constructs was assessed by western blotting cell extracts with bFGF antibody.

**Thymidine uptake**

Cells were plated in 96-well plates (3 × 10³ cells/well). After 4 h, cells were incubated with 0.5 μCi/well Methyl-[³²P]-Thymidine (Perkin Elmer, Waltham, MA, USA) for 16 h before harvesting onto glass-fiber filters. [³²P]-Thymidine incorporation was measured as counts per minute (CPM) using a Tri-Carb 2100TR time-resolved liquid scintillation counter (Perkin Elmer, Waltham, MA, USA).

**Alamar blue**

Cells were plated in 96-well black, clear-bottom plates (2 × 10³ cells/well) in 100 μl complete medium. After 4 h, 10 μl/well Alamar Blue (Life Technologies) reagent was added. After 2 h, fluorescence was measured using a Cytation3 plate reader (BioTek).

**shRNA and addback transfection**

Cells were grown to 50 % confluence in a 10-cm dish. The transfection mixtures contained: 1) 2 μg bFGF shRNA (Sigma, St. Louis, MO; clone # NM_02006.x-635s1c1; catalog # TRCN0000003330) or control shRNA plasmid (Sigma, St Louis, MO, USA; pLKO.1) + Optimem (Life Technologies) and 2) Lipofectamine 2000 (Life Technologies) + Optimem. These mixtures were incubated separately at room temperature for 5 minutes, combined, and incubated for 30 minutes at room temperature. Cells were washed twice with HBSS (Life Technologies). Optimem was then added to the RNA/Lipofectamine mixture, and the mix was added to the cells, which were incubated overnight at 37 °C. This medium was removed the next day and replaced with media containing puromycin (5 μg/ml, SUM159; 2 μg/ml, BT549). Cells were expanded in puromycin and tested for bFGF knockdown by western blotting. For bFGF addback, plasmids [25] expressing 18-kDa rat bFGF, 23-kDa rat bFGF, or an empty control vector were transfected into SUM159 or BT549 cells stably expressing a bFGF shRNA. The transfection protocol was performed as above, except that the cells were selected in puromycin (as above) and G418 (Life Technologies) at 400 μg/ml. Expression of addback constructs was assessed by western blotting cell extracts with bFGF antibody.

**Single cell gel electrophoresis assay (comet assay)**

Cells were challenged with doxorubicin (SUM159: 1 μg/ml, 3 h; BT549: 0.5 μg/ml, 4h). Fresh medium was added after chemotherapy removal. Cells were harvested at sequential time points after chemotherapy, mixed with low-melting-point agarose, and spread on comet slides using a Trevigen CometAssay® Kit (Trevigen Inc., Gaithersburg, MD, USA). After incubation with lysis solution and neutral solution,
slides were subjected to electrophoresis at 19 V for 50 minutes under neutral conditions. Slides were incubated with DNA precipitation solution (1 M NH₄AC, 95 % EtOH) for 30 minutes, followed by 70 % ethanol for 30 minutes. Slides were then stained with a 1:500 dilution of Hoechst (Life Technologies) for 15 minutes and washed with PBS. Samples were examined using a fluorescence microscope, and the presence of comet tails was quantified using Gen5 image analysis software (BioTek). Cells from three fields were analyzed for each time point. Each field contained at least 50 cells.

**Real-time quantitative RT-PCR**

Total RNA from SUM159 cells was extracted using PrepEase® RNA Spin Kit (USB, Cleveland, OH, USA) and treated with RNase-free DNase to remove residual genomic DNA. Single-stranded cDNAs were synthesized using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Human fibroblast growth factor-2 (FGF2) and human DNA-PKcs primers were purchased from realtimeprimers.com (Elkins Park, PA, USA). Real-time PCR on the Mx3005P® QPCR System (Stratagene, La Jolla, CA, USA) was performed in the presence of 12.5 μl VeriQuest™ Fast SYBR Green qPCR Master mix (2×) (USB, Cleveland, OH), 2 μl cDNA, and H₂O added to a final volume of 25μl. The mixtures were denatured for 5 minutes at 95 °C, followed by 40 cycles of 3 s at 95 °C, and 30 s at an annealing temperature at 60 °C. PCR products were monitored in real time by measuring the increase in fluorescence caused by the binding of SYBR Green 1 Dye. Significance was analyzed using the software package MxPro™ QPCR Software (Stratagene, La Jolla, CA, USA).

**Selective DNA-PK inhibitor (NU7441) studies**

Cells were seeded in T225 cell culture flasks (2 × 10⁶ cells/flask) and, after 2 days, treated with 1 μg/ml doxorubicin (Sigma) plus dimethyl sulfoxide (DMSO) or NU7441 (1 μM or 5 μM, R&D Systems, Minneapolis, MN, USA). The drug was removed after 2 days, and cells were fed with new medium every third day. Chemo-resistant cells were harvested on day 7 with trypsin-EDTA, and re-plated in 6-well plates. Medium was changed every 3 to 4 days. Colonies evolving from chemo-residual cells were stained with crystal violet. Colonies containing >50 cells were counted.

**Immunohistochemistry of patient tumors**

TN breast cancer patients treated with neoadjuvant chemotherapy that exhibited an incomplete pathologic response were identified from medical records under Duke Institutional Review Board approval (protocol 47289). Retrospectively collected tumor biopsies (obtained pre-chemotherapy) and biopsies/resections (obtained post-chemotherapy) from these patients were retrieved. Formalin-fixed, paraffin-embedded tissues were subjected to bFGF immunohistochemistry. Slides were baked at 60 °C for 1 h, and deparaffinized in xylene followed by 100 % ethanol. Antigen retrieval was performed in sub-boiling EDTA (pH 8) at 100 °C for 40 minutes. bFGF staining was performed in an autostainer according to the following program: Endogenous Peroxidase Quench (Cell Marque Rocklin, CA, USA) 5 minutes; Protein block (Biocare Medical, Concord, CA, USA), 10 minutes; bFGF antibody (BD Biosciences, Franklin Lakes, NJ, USA; catalog # 610073 (1:250 dilution), 1 h; secondary detection kit (Cell Marque, Rocklin, CA, USA), 20 minutes; 3,3-diaminobenzidine (DAB), 5 minutes; hematoxylin, 1 minute; and Bluing, 1 minute. Slides were then placed in water and dehydrated in xylene before adding a coverslip.

**bFGF immunohistochemistry scoring**

Two pathologists (GD, RA) (blinded to patient samples) assigned scores for the percentage of nuclear bFGF-positive cells and percentage of cytosolic bFGF-positive cells. The scoring of all cases was confirmed by a board-certified pathologist (SVP).

**Results**

**Chemo-residual TN breast cancer cells express increased nuclear bFGF**

To enrich for chemo-resistant tumor cells, we treated SUM159 and BT549 TN breast tumor cells with doxorubicin at a clinically relevant concentration [26]. Doxorubicin was removed after 2 days, and fresh medium was added. Although the vast majority of cells were eliminated by day 6, we observed a small number of residual, viable tumor cells, representing 0.1 % of the original population, on day 7 post treatment (Fig. 1a). These chemo-residual cells were metabolically active, but exhibited significantly reduced proliferation (Fig. 1b). Chemo-residual tumor cells resumed proliferation approximately 2 weeks post chemotherapy treatment. Our previous studies show that colonies from this model continue to expand after 18 days, and exhibit resistance to multiple classes of chemotherapy for as long as 50 days [8].

Previous studies suggest that continuous chemotherapy selection models promote the growth of cancer stem-like cells [27–29]. Accordingly, we investigated if chemo-residual tumor cells from our short-term chemotherapy treatment model behaved like cancer stem-like cells. As shown in Fig. 1c, d, chemo-residual TN tumor cells in our model did not exhibit increased mammosphere-forming ability. Continuous chemotherapy treatment of TN breast cancer cells has also been shown to drive hypoxia inducible factor-1α (HIF-1α) expression, a critical determinant of cancer stemness [28]. In contrast, chemo-residual tumor cells emanating from our short-term chemotherapy treatment model exhibited reduced HIF-1α expression.
Fig. 1 (See legend on next page.)
mRNA (Fig. 1e) and protein (Fig. 1f) levels. Collectively, these findings suggest that chemo-residual tumor cells evolving from our short-term chemotherapy treatment model are different from previously defined cancer stem-like cells selected by continuous chemotherapy treatment models.

bFGF signaling has been implicated in tumor resistance to targeted therapies [10–15]. Accordingly, we investigated bFGF expression in chemo-residual TN tumor cells from our short-term chemotherapy treatment model. As shown in Fig. 2a, we observed significantly increased bFGF mRNA expression in chemo-residual tumor cells compared to parental cells. To further elucidate the connection between different isoforms of bFGF and chemo-resistance, we measured nuclear and cytosolic bFGF levels in chemo-residual TN tumor cells. On western blots, significantly increased levels of nuclear bFGF isoforms (22, 24 kDa), but not the cytosolic bFGF isoform (18 kDa), were detected in chemo-residual cells compared to parental cells (Fig. 2b). This trend was observed regardless of the chemotherapy class studied (doxorubicin or docetaxel, Fig. 2b). By immunofluorescence, we confirmed increased nuclear bFGF in chemo-residual cells relative to parental cells for both SUM159 and BT549 tumor cells (Fig. 2c) and for two other TN breast cancer cell lines (HS78T and MDA-MB-231, data not shown). These results suggest an association between nuclear bFGF expression and TN breast cancer chemo-resistance.

bFGF is essential for the survival of chemo-residual tumor cells and subsequent colony formation

Studies in Fig. 2 indicate that nuclear bFGF is upregulated in chemo-residual TN breast cancer cells. To determine whether bFGF is required for TN breast cancer chemo-resistance, we knocked down bFGF expression in SUM159 and BT549 cells by stable bFGF shRNA transfection (Fig. 3a). Cells transfected with bFGF or control shRNA were treated for 2 days with doxorubicin as in Fig. 1a. The number of doxorubicin-enriched chemo-residual cells on day 7 was significantly decreased in bFGF shRNA transfectants compared to control shRNA transfectants (Fig. 3b, c). Moreover, bFGF shRNA-transfected chemo-residual cells formed dramatically fewer colonies after chemotherapy removal than control shRNA transfectants (Fig. 3d, e). Similar results were observed in two TN breast cancer cell lines (SUM159, BT549; Fig. 3d, e). These results indicate that bFGF is necessary for the survival of chemo-residual tumor cells after doxorubicin challenge and for their subsequent proliferation upon chemotherapy withdrawal.

Nuclear bFGF promotes the survival of chemo-residual tumor cells and subsequent colony formation

To determine which bFGF isoform facilitates chemo-residual tumor cell survival and colony formation in our model, we transfected bFGF shRNA-expressing cells with a vector expressing 18-kDa rat bFGF, 23-kDa rat bFGF, or an empty control vector (Fig. 4a). The 18-kDa and 23-kDa rat bFGF constructs exhibit 97 % and 82 % homology with human 18-kDa and 24-kDa nuclear bFGF, respectively [30]. The addback of the 23-kDa rat nuclear bFGF, but not the 18-kDa rat cytosolic bFGF, to bFGF shRNA transfectants increased the number of chemo-residual tumor cells to that observed in control cells (Fig. 4b). Likewise addback of the 23-kDa bFGF isoform restored the ability of bFGF shRNA-transfected chemo-residual cells to establish colonies (Fig. 4c, d) following short-term doxorubicin treatment. Of note, similar transfection of SUM159 cells expressing the control shRNA did not influence cell viability (data not shown).
Collectively, our results demonstrate that high molecular weight (nuclear) bFGF, but not low molecular weight (cytosolic) bFGF, is sufficient to maintain the viability of chemo-residual tumor cells and promote subsequent colony growth after chemotherapy withdrawal.

**bFGF regulates DNA-PK expression/activity and is associated with accelerated DNA double strand break repair in chemo-residual TN tumor cells**

Elevated DNA repair activity is associated with chemoresistance in many tumors [31–34]. To compare the DNA double-strand break (DSB) repair capability, we re-challenged untreated parental cells and chemo-residual cells with doxorubicin (a DNA-damaging agent) for 3 h and examined their recovery by neutral comet assay. As shown (Fig. 5a, b) the percent cells with comet tails returned to baseline quicker in chemo-residual cells than in parental cells. Similar results were observed in both SUM159 (Fig. 5a) and BT549 (Fig. 5b) chemo-resistance models. These data indicate that chemo-residual TN tumor cells from our short-term chemotherapy treatment model repaired DNA strand breaks more quickly than parental cells.

DNA-PK is the key protein responsible for non-homologous end joining (NHEJ) of DNA DSBs. Overexpression of bFGF in HeLa cells drives the expression and activation of DNA-PK<sub>CS</sub> [20]. To determine whether DNA-PK<sub>CS</sub> is a downstream target of nuclear bFGF in our TN breast cancer chemo-resistance model, we determined the expression level of DNA-PK<sub>CS</sub> in chemotherapy-enriched TN tumor cells. Chemo-residual TN tumor cells expressed increased levels of both DNA-PK<sub>CS</sub> and phospho-(Ser-2056)-DNA-PK<sub>CS</sub>, representing the activated form of DNA-PK<sub>CS</sub> [35] (Fig. 5c).

**Inhibition of DNA DSB repair by a selective DNA-PK inhibitor decreases the survival of chemo-residual tumor cells and subsequent colony formation**

NU7441 is a specific inhibitor of DNA-PK with 100-fold selectivity for DNA-PK, compared to other PI3K kinase...
family members [36, 37]. To determine whether DNA-PK inhibition reduces TN chemo-residual tumor cell survival and regrowth, we simultaneously treated SUM159 TN breast tumor cells with doxorubicin and NU7441 at either of two non-cytotoxic concentrations [36]. NU7441 significantly decreased the number of chemo-residual cells (Fig. 6a) and subsequent colony formation (Fig. 6b) in a concentration-dependent manner. Previous preclinical studies indicate that the DNA-PK inhibitor NU7441 synergizes with chemotherapy to
reduce tumor growth in a colon cancer model [36]. Our results suggest the importance of testing the efficacy of combination therapy (NU7441 + chemotherapy) for TNBC in future preclinical studies.

**Nuclear bFGF drives accelerated DNA repair and DNA-PKcs expression in chemo-residual TN tumor cells**

We next investigated the effects of bFGF knockdown on DNA repair in chemotherapy-challenged TN breast tumor cells. Twenty-four hours after doxorubicin challenge, SUM159 cells expressing a bFGF shRNA had a similar level of DNA damage to that of cells expressing a control shRNA, with approximately 70% of cells having a comet tail (Fig. 7a). However, control shRNA-expressing cells exhibited more rapid DNA repair than bFGF shRNA transfectants, with only approximately 30% of control shRNA-expressing cells having comet tails at 48 h post challenge (compared to approximately 60% of bFGF shRNA-expressing cells having comet tails at this time) (Fig. 7a). To determine which bFGF isoform drives repair in these cells, we next performed comet assays on knockdown cells reconstituted with low molecular weight (LMW) or high molecular weight (HMW) bFGF. As shown in Fig. 7b, bFGF knockdown cells exhibited significantly slower DNA repair than control cells. Moreover, expression of HMW bFGF, but not LMW bFGF, in bFGF knockdown cells restored DNA repair to the level observed in control shRNA cells (Fig. 7b).

Based on our observation that DNA repair in chemo-residual cells was associated with increased nuclear bFGF and increased DNA-PKcs levels, we next investigated effects of bFGF knockdown on DNA-PKcs expression. bFGF knockdown significantly decreased the DNA-PKcs protein level in chemotherapy-enriched tumor cells, indicating upstream regulation of DNA-PKcs by bFGF (Fig. 7c). Expression of HMW bFGF, but not LMW bFGF, in bFGF knockdown cells increased DNA-PKcs levels (Fig. 7d). In contrast, expression of HMW bFGF did
not influence DNA-PKcs levels in control shRNA cells (data not shown). Collectively, these results suggest that chemo-residual tumor cells support a bFGF/DNA-PK signaling axis that confers accelerated DNA DSB repair capability, allowing them to survive chemotherapy challenge.

**Percentage of nuclear bFGF-expressing tumor cells is increased or maintained in a subset of residual tumors from TN breast cancer patients**

To validate our findings in patients with TN breast cancer, we optimized an immunohistochemistry (IHC) protocol for detecting nuclear and cytosolic bFGF in formalin-fixed,
paraffin-embedded tissues. In a pilot study, we selected nine patients with TN breast cancer that exhibited an incomplete pathologic response to neoadjuvant chemotherapy treatment. Matched samples from patients with TN breast cancer (Fig. 8), obtained before and after neoadjuvant chemotherapy treatment, were stained with bFGF antibody. As shown in Table 1, in five of nine patients, the percentage of nuclear bFGF+ tumor cells increased or remained the same in the post-treatment samples compared to those obtained pre-treatment. In contrast, in four of nine patients with TNBC, the percentage of nuclear bFGF+ tumor cells decreased post-treatment. These data demonstrate that nuclear bFGF-positive cells are enriched in a subset of patients with TN breast cancer following neoadjuvant chemotherapy treatment. Of note, the percentage of cytosolic bFGF+ tumor cells did not follow the same trends pre-treatment versus post treatment as did the percentage of nuclear bFGF+ tumor cells for these patients (data not shown).
Fig. 7 Nuclear basic fibroblast growth factor (bFGF) drives DNA repair and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression. 

**a** Left panel: BT549 cells transfected with bFGF shRNA or control (ctrl) shRNA were challenged with doxorubicin (Dox) (0.25 μg/ml) for 2 h. Fresh medium was added after chemotherapy removal. DNA damage at sequential time points after chemotherapy treatment was analyzed by neutral comet assay. Representative images are shown for each time point. Cells scored as comet tail-positive are indicated with red arrows in the 48-h time frame. 

Right panel: percentage of cells with comet tails at indicated time points was quantified with a fluorescence microscope. Error bars represent SD, n = 3 fields (each field containing >50 cells). Significance of data points at 24 and 48 h was determined relative to data reported at 0 h for the indicated cell population (*p <0.05, **p <0.01, ***p <0.001, two-tailed Student’s t test). 

**b** SUM159 cells expressing control shRNA, bFGF shRNA, or bFGF shRNA plus indicated addback constructs (as in Fig. 4a) were challenged with doxorubicin (0.25 μg/ml) for 2 h. Fresh medium was added after chemotherapy removal. DNA damage at sequential time points after chemotherapy treatment was analyzed by neutral comet assay. Percentage of cells with comet tails at the indicated time points was quantified with a fluorescence microscope. Error bars represent SD, n = 3 fields (each field containing >50 cells). Significance of data points at 24 and 48 h was determined relative to data reported at 0 h for the indicated cell population (*p <0.05, **p <0.01, ***p <0.001, two-tailed Student’s t test). 

**c** SUM159 and BT549 cells transfected with bFGF shRNA or ctrl shRNA were treated with doxorubicin as in Fig. 1a. Nuclear protein from chemo-residual cells was extracted. Equivalent amounts were immunoblotted with DNA-PKcs and lamin A antibodies. Protein bands were quantified, and the relative ratio of DNA-PKcs to loading control is shown for each lane. 

**d** Left panel: bFGF shRNA-transfected SUM159 cells expressing indicated addback constructs were treated with doxorubicin as in Fig. 1a. Nuclear protein from chemo-residual cells was extracted. Equivalent amounts were immunoblotted with DNA-PKcs and lamin A antibodies. Protein bands from three independent trials were quantified and the relative ratio of DNA-PKcs to loading control is shown for each line. Error bars represent SD, n = 3, **p <0.01, two-tailed Student’s t test.
Discussion

Previous chemotherapy selection models have shown the relevance of cancer stem-like cells in TN breast cancer chemo-resistance [27, 28]. In one of these studies, HIF-1α was shown to be a central determinant of TN cancer stem-like cell chemo-resistance [27]. Our model is distinct from these studies in identifying a chemo-resistant TN tumor cell subpopulation enriched after 2 days of chemotherapy treatment followed by a rest period (6 days) during which chemotherapy is removed. We propose that this model is pertinent to the drug holiday experienced in patients between chemotherapy cycles. Notably, chemo-resistant cells from our model differ from those arising after continuous chemotherapy treatment. First, chemo-residual TN tumor cells from our model do not exhibit enhanced mammosphere forming ability (Fig. 1c, d), indicating that they do not demonstrate cancer-stem-like cell behaviors. Moreover, HIF-1α, previously implicated in cancer stem-cell chemo-resistance [28], is downregulated in chemo-residual TN tumor cells from our model (Fig. 1e, f). We hypothesize that continuous chemotherapy treatment is necessary to maintain a cancer stem-like cell population, a topic of current investigation in our laboratory. In contrast, our short-term chemotherapy treatment model identifies a chemo-resistant population that is maintained after chemotherapy removal, and that exhibits increased DNA repair capability driven by a nuclear bFGF signaling axis.

Novel markers of TN breast cancer chemo-resistance were recently identified by performing microarray on

**Table 1** Nuclear bFGF expression in triple-negative breast tumors before and after neoadjuvant chemotherapy treatment

<table>
<thead>
<tr>
<th>TNBC patients</th>
<th>Chemotherapy</th>
<th>Nuclear bFGF(+) cells pre-chemotherapy (%)</th>
<th>Nuclear bFGF(+) cells post-chemotherapy (%)</th>
<th>Trend (post-chemotherapy versus pre-chemotherapy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ACT</td>
<td>50</td>
<td>90</td>
<td>Increase</td>
</tr>
<tr>
<td>2</td>
<td>TC</td>
<td>1</td>
<td>50</td>
<td>Increase</td>
</tr>
<tr>
<td>3</td>
<td>AC</td>
<td>0</td>
<td>100</td>
<td>Increase</td>
</tr>
<tr>
<td>4</td>
<td>TAC</td>
<td>100</td>
<td>100</td>
<td>=</td>
</tr>
<tr>
<td>5</td>
<td>AC</td>
<td>100</td>
<td>100</td>
<td>=</td>
</tr>
<tr>
<td>6</td>
<td>AC + 1 × paclitaxel</td>
<td>30</td>
<td>20</td>
<td>Decrease</td>
</tr>
<tr>
<td>7</td>
<td>ACT</td>
<td>70</td>
<td>20</td>
<td>Decrease</td>
</tr>
<tr>
<td>8</td>
<td>ACT</td>
<td>90</td>
<td>25</td>
<td>Decrease</td>
</tr>
<tr>
<td>9</td>
<td>AC + 1 × paclitaxel</td>
<td>100</td>
<td>15</td>
<td>Decrease</td>
</tr>
</tbody>
</table>

Nine patients with triple-negative breast cancer (TNBC) exhibiting an incomplete pathologic response to neoadjuvant chemotherapy were identified from medical records under Duke Institutional Review Board approval (protocol 47289). Chemotherapy regimen is indicated (A Adriamycin, C cyclophosphamide, T Docetaxel). Basic fibroblast growth factor (bFGF) expression in formalin-fixed, paraffin-embedded tissues was assessed by immunohistochemistry using bFGF antibody. Nuclear bFGF scoring was performed in a blinded fashion by two pathologists. Consensus scores for percent nuclear bFGF(+) cells are shown. Three of nine patients had increased percent nuclear bFGF(+) cells post-chemotherapy (Increase), two of nine patients had sustained % nuclear bFGF(+) cells post-chemotherapy (=), and four of nine patients had reduced % nuclear bFGF(+) cells post-chemotherapy (Decrease). For the two patients in which % nuclear bFGF(+) cells remained the same post-treatment, 100 % of tumor cells pre-treatment were nuclear bFGF(+). In summary, five of nine cases showed increased or sustained percent nuclear bFGF(+) cells post chemotherapy.

![Fig. 8](image_url) Nuclear basic fibroblast growth factor (bFGF) expression is increased in a subset of triple-negative (TN) breast cancers post neoadjuvant chemotherapy treatment. bFGF immunohistochemistry was performed on matched tumor tissues obtained from a patient with TN breast cancer before (pre-chemotherapy) and after (post-chemotherapy) neoadjuvant chemotherapy (docetaxel/cyclophosphamide) treatment. Magnification ×200.
patient tumor samples obtained before and after neoadjuvant chemotherapy treatment [38]. It is important to note, however, that microarray analyses will not identify chemo-resistance markers regulated at the translational or post-translation level. Our study is unique in studying proteins that are upregulated in chemo-residual TN tumor cells. Using a short-term chemotherapy enrichment model, we have identified a nuclear bFGF isoform, the expression of which is dependent on cap-independent protein translation, that determines survival of TN chemo-residual tumor cells.

Expression of nuclear versus cytosolic bFGF isoforms is determined by alternative translation pathways. Whereas cytosolic bFGF isoforms are regulated by cap-dependent translation, nuclear bFGF isoforms are regulated by cap-independent translation. Notably, we observed increased protein levels of nuclear but not cytosolic bFGF isoforms in chemo-residual tumor cells. Our data suggest that chemo-residual tumor cells may support cap-independent translation, driving expression of nuclear bFGF and DNA repair. We are currently addressing this important hypothesis. Ultimately, it may be possible to eliminate these chemo-residual tumor cells by targeting the cap-independent translation pathway.

Previous studies indicate that tumor resistance to anti-angiogenic therapy is associated with increased expression of cytosolic FGF, which is able to restore tumor angiogenesis [10–15]. Accordingly, we were surprised to observe upregulation of nuclear bFGF isoforms, but not cytosolic bFGF isoforms, in chemo-residual tumor cells. Our studies suggest that nuclear bFGF may drive TN breast cancer resistance in a manner independent of angiogenesis.

We observed that chemo-residual cells, relative to parental SUM159 tumor cells, express increased levels of both the 22-kDa and the 24-kDa nuclear forms of bFGF (Fig. 1d). In order to determine whether both nuclear bFGF isoforms are critical to our model, we performed addback studies using a 23-kDa rat nuclear bFGF construct (exhibiting 82 % homology with human 24-kDa nuclear bFGF). This 23-kDa bFGF isoform alone was able to restore chemo-resistance by promoting chemo-residual cell survival and regrowth in SUM159 cells expressing bFGF shRNA. Our data indicate that the survival function of this 23-kDa bFGF isoform relates to its ability to drive DNA repair.

We also observed that bFGF RNA levels are increased in chemo-residual tumor cells relative to parental tumor cells (Fig. 1c). Identifying signaling pathways that increase bFGF transcription/mRNA stability in chemo-residual cells has the potential to identify rational methods for targeting these chemo-resistant tumor cells. Of note, previous studies indicate that hypoxia drives bFGF transcription in an HIF-1-dependent manner [39]. However, we did not see HIF-1 expression elevated in chemotherapy-enriched tumor cells (Fig. 2e), suggesting an alternative driver of bFGF mRNA expression in chemo-residual tumor cells.

Our work identifies DNA-PKcs as a downstream target of nuclear bFGF in chemo-residual TN tumor cells. DNA-PKcs has previously been implicated in therapy resistance [31–34]. Long term chemotherapy selection models have been shown to select for chemo-resistant tumor cells with increased DNA-PKcs expression/activity [34, 40]. The current study is unique in identifying a nuclear growth factor (nuclear bFGF) in chemo-residual tumor cells that drives DNA repair and DNA-PKcs expression. Notably, nuclear bFGF did not increase DNA-PKcs mRNA levels, as assessed by real-time PCR (data not shown). Further work is needed to determine the mechanism by which nuclear bFGF increases DNA-PKcs expression/activity. In addition, we are investigating the ability of nuclear bFGF to activate other DNA repair pathways.

We also found that a small molecule inhibitor of DNA-PKcs reduced both the number of chemo-residual tumor cells (Fig. 7) and the number of colonies evolving after chemotherapy withdrawal (Fig. 7) in our in vitro model of TN breast cancer chemo-resistance. This activity may be attributed to multiple reported activities of DNA-PK. This DNA-PK inhibitor likely reduces the number of chemo-residual tumor cells by blocking DNA repair, leading to increased tumor cell apoptosis. However, this inhibitor may also chemo-sensitize TN tumor cells by inhibiting a recently reported, non-conventional activity for DNA-PK, namely its ability to induce AKT-dependent cell survival [41]. Finally, DNA-PK is a critical regulator of mitosis [42]. Thus, it is possible that inhibiting DNA-PK in our model prevents the transition of chemo-residual tumor cells to proliferative colonies.

Nuclear-localized EGF receptor is a central determinant of DNA-PK activity [43]. Based on this knowledge, in addition to our current findings, it is intriguing to speculate that nuclear bFGF may control DNA-PKcs expression/activity in a manner dependent on a nuclear bFGF receptor, a topic of current investigation. This possibility is supported by the literature, which demonstrates that nuclear FGF cooperates with a nuclear FGF receptor to drive gene transcription in neurons [44]. Identifying a bFGF receptor that drives nuclear bFGF/DNA-PK signaling has the potential to define a logical therapeutic strategy (i.e., combining chemotherapy with an FGF receptor small molecule inhibitor) to eliminate chemo-residual TN breast cancer cells, thus preventing tumor recurrence.

Our studies of TN breast cancer samples obtained before and after neoadjuvant chemotherapy treatment demonstrate that a subset of these patients exhibit
increased percentage of nuclear bFGF-positive cells post treatment. These data validate our in vitro findings, showing that chemotherapy enriches for nuclear bFGF-positive cells. All of these patients received either anthracycline or anthracycline + taxane therapy, and exhibited an incomplete pathologic response. While 56% of matched samples exhibited increased or sustained nuclear bFGF-positive cells, 44% of matched samples exhibited reduced nuclear bFGF-positive cells post neoadjuvant chemotherapy. Considering that multiple TN breast cancer subtypes have been identified [45], we hypothesize that nuclear bFGF-positive cells may only be enriched in a subset of TN breast cancer subtypes. The role of homologous recombination deficiency (HRD), commonly mediated by loss of BRCA1/2 activity, in chemo-responsiveness is not well-defined, and is actively being investigated (NCT01982448). The HRD/BRCA status of TN breast cancer patients may also influence whether a nuclear bFGF/DNA-PK signaling axis determines chemotherapy resistance. We hypothesize that with follow up the 56% of patients with increased or sustained percentage of nuclear bFGF-positive cells will exhibit future tumor recurrence. These pilot data underscore the importance of performing a large-scale prospective study of nuclear bFGF expression in TN breast cancer cases before and after neoadjuvant chemotherapy treatment, controlling for BRCA status and TN breast cancer subtype. These follow-up studies have the potential to identify a novel biomarker in a subset of TN breast cancer patients that predicts chemotherapy resistance and future tumor recurrence. In addition, identifying nuclear bFGF as a determinant of chemoresistance in a subset of TN breast cancers will establish a logical therapeutic strategy for chemo-sensitizing tumors in these patients.

Conclusions

Using a short-term chemotherapy enrichment model, we demonstrated a critical role for nuclear bFGF in TN breast cancer chemotherapy resistance. Notably, previous continuous chemotherapy selection models did not identify nuclear bFGF as a driver of TN breast cancer chemoresistance. To begin to demonstrate the relevance of our findings to the clinic, we showed that nuclear bFGF-positive tumor cells were increased or maintained in the majority of patients with TN breast cancer post neoadjuvant chemotherapy treatment. Follow-up studies are needed to determine if nuclear bFGF expression in TN breast cancer cells predicts an incomplete pathologic response and/or future tumor recurrence in patients with TN breast cancer.

Chemotherapy remains the core therapy for TN breast cancer and studies of new agents will likely continue to be done in combination with chemotherapy for the foreseeable future. Our studies suggest that nuclear bFGF maintains survival of a chemo-resistant subpopulation that then drives metastatic recurrence. Developing therapies that target this mechanism may be essential for overcoming this chemo-resistance and reducing TN breast cancer-associated mortality.

Abbreviations

bFGF: Basic fibroblast growth factor (FGF-2); DMSO: Dimethyl sulfoxide; DNA-PK: DNA-dependent protein kinase; DNA-PKcs: DNA-dependent protein kinase catalytic subunit; DSb: Double-strand break; FBS: Fetal bovine serum; HBSS: Hank’s balanced salt solution; HER2: Human epidermal growth factor receptor-2; HIF-1α: Hypoxia inducible factor-1α; HMW: High molecular weight; HRD: Homologous recombination deficiency; LMW: Low molecular weight; PBS: phosphate-buffered saline; RPMI: Roswell Park Memorial Institute; shRNA: Short-hairpin RNA; TN: Triple-negative; TNBC: Triple-negative breast cancer.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SL, SP, FW, PC, ZS, JGer, PKM, and REB conceived and designed the experiments. SL, SP, FW, ZS, and JGr performed the experiments. SL, SP, FW, SVP, GD, RA, JGer, PKM, SVP, and REB analyzed the data. SL, SP, FW, PC, ZS, JGr, JGer, GD, RA, PKM, SVP, and REB drafted the manuscript. All authors have read and approved the final manuscript. All authors meet the three authorship requirements for this journal.

Acknowledgements

We thank Margaret Kennedy, and Drs Rupa Ray, Vendula Pospichalova, Kelly Kilibarda, George Cianciolo, Xiao-Fan Wang, and Mark Dewhirst for their useful comments. This work was supported by Department of Defense Congressionally Directed Medical Research grant W81XWH-13-1-0404 (REB).

Author details

1Department of Pathology, Duke University Medical Center, P.O. Box 3712, Durham, N.C. 27710, USA. 2Duke Cancer Institute, Durham, N.C. 27710, USA. 3Institute of Neuroanatomy, Hannover Medical School, Hannover, Germany.

Received: 21 October 2014 Accepted: 19 May 2015

Published online: 04 July 2015

References


Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

www.biomedcentral.com/biomedcentral